| 摘要 |
A method for decreasing blood glucose levels is disclosed. Iptakalim hydrochloride (a SUR1 subunit-dependent K<SUB>ATP </SUB>channel blocker and a SUR2 subunit-selective K<SUB>ATP </SUB>channel opener) is used to block pancreatic beta-cell K<SUB>ATP </SUB>channels, which depolarizes beta-cells, elevates intracellular Ca<SUP>2+</SUP> concentrations, and in turn increases insulin release. Therefore, in some implementations, iptakalim hydrochloride is an optimal treatment for type-2 diabetic patients with cardiovascular disorders.
|
